Evidence map›Paper›PMID 23053321›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2013

Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.

Ana María García Vicente, Angel Soriano Castrejón, Miguel Angel Cruz Mora, Ana González Ageitos, María del Mar Muñoz Sánchez, Alberto León Martín, Ruth Espinosa Aunión, Fernanda Relea Calatayud, Vicente Muñoz Madero, Ignacio Chacón López-Muñiz and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Examining the evolving utility ofTranslational cancer research · 2020
    Review
  5. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ana María García VicenteNuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n, Ciudad Real, Spain. angarvice@yahoo.es
Angel Soriano Castrejón
Miguel Angel Cruz Mora
Ana González Ageitos
María del Mar Muñoz Sánchez
Alberto León Martín
Ruth Espinosa Aunión
Fernanda Relea Calatayud
Vicente Muñoz Madero
Ignacio Chacón López-Muñiz
Jose Manuel Cordero García
Germán Andrés Jiménez Londoño
Hospital General Universitario de Ciudad Real · ESHospital Virgen de la Salud · ESComplejo Hospitalario Universitario de Toledo · ESHospital General Nuestra Señora del Prado · ESHospital Virgen de la Luz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to analyse the correlation between dual-time-point (18)F-2-deoxy-2-fluoro-D-glucose (FDG) uptakes in lymph nodes assessed by positron emission tomography (PET)/CT and histopathological and immunohistochemical prognostic factors.

methodsSeventy-five women with locally advanced breast cancer were prospectively evaluated. PET/CT was requested in the initial staging previous to adjuvant chemotherapy (multicentre study). All of the patients underwent (18)F-FDG PET/CT with a dual-time-point acquisition. Both examinations were evaluated qualitatively and semi-quantitatively with calculation of maximum standardized uptake values (SUV(max)) in PET-1 (SUV-1) and in PET-2 (SUV-2) and the percentage variation of the SUV or retention index (RI) between PET-1 and PET-2 in lymph nodes with the greater (18)F-FDG uptake. The biological prognostic parameters such as the steroid receptor status, p53 and HER2 expression, proliferation rate (Ki-67) and grading were determined from tissue of the primary tumour. Metabolic and biological parameters were correlated using Spearman's rank-order correlation coefficient and Mann-Whitney U and Kruskal-Wallis tests.

resultsNegative receptor status was correlated with higher SUV-1, SUV-2 and RI in lymph nodes. The results were significant for progesterone receptor status. p53 over-expression and triple-negative status were associated with greater semi-quantitative parameters in lymph nodes. Higher tumoural grades were related with greater semi-quantitative parameters (p > 0.05).

conclusionBiological factors of bad prognosis were correlated with higher semi-quantitative metabolic values in lymph nodes. Therefore these results appear to reveal biological significance of lymph node (18)F-FDG accumulation.

Indexed as

Fluorodeoxyglucose F18Multimodal ImagingPositron-Emission TomographyTomography, X-Ray ComputedAdultAgedBreast NeoplasmsCell ProliferationChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansLymph NodesMiddle AgedNeoplasm StagingPrognosisERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Receptors, SteroidTumor Suppressor Protein p53

Identifiers

PMID23053321
OpenAlexW1982266308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.